Immunology Platform into Autoimmune Diseases

Evaxion A/S (NASDAQ: EVAX) will present new immune data for its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The data comes from a phase 2 trial of EVX-01 combined with pembrolizumab in advanced melanoma patients, showing a 75% objective response rate. Full three-year data will be presented at ESMO 2026, including insights on the vaccine's effects as a standalone therapy.

Evaxion A/S (EVAX) reported a Q2 2026 net loss of $3.7M, improving from the prior year. Cash reserves totaled $14M, extending runway into 2H 2027. The company advanced its cancer and infectious disease vaccine pipeline, with key data presentations and regulatory filings expected. EVAX stock rose 6.35% in pre-market trading.

Evaxion A/S (EVAX) reported Q2 2026 financial results, including a net loss of $3.7M. The company highlighted progress in its R&D pipeline, including upcoming data presentations for cancer vaccine candidates EVX-01, EVX-04, and EVX-05, as well as CMV vaccine EVX-V1. Evaxion also won the 2026 Prix Galien UK Award for Best digital health solution. The company expects its cash runway to extend into the second half of 2027.

Evaxion A/S (EVAX) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Evaxion announces business update and second quarter 2026 financial results COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides

Google launched Gemini 4 Argon, its flagship AI model, for developers and businesses, with pricing starting at $2 per million input tokens. The model is designed for complex tasks in coding, finance, and other fields. Google aims to compete with OpenAI and Anthropic after recent setbacks. Early customers include Deloitte and LexisNexis. The company also expanded its Fairwind Program for cybersecurity partners.

Meta introduced new AI models, Muse Wonder and Muse Wonder Full, claiming state-of-the-art performance in tasks like coding, finance, and health. The stock rose 2.5% on the news. JPMorgan raised its price target to $920, citing Muse's potential as a leading consumer AI application. Meta also unveiled a hardware device, Muse Charm, for AI interaction.